NL-OMON52124尚未招募4 期
A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients - ENVAD-HF
niversity of Zagreb School of Medicine0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Written informed consent must be obtained before any assessment is performed.
- •2. >=18 years of age, male or female
- •3. Recently implanted HeartMate 3 LVAD recipients, in stable condition and
- •deemed ready for discharge or chronic, stable, ambulatory HeartMate 3 LVAD
- •carriers implanted within 1 year prior to enrolment
排除标准
- •1. Current acute decompensated HF (including right ventricular failure)
- •requiring therapy with intravenous diuretics or vasodilators and/or inotropic
- •drugs within the past 48 hours
- •2. History of hypersensitivity to sacubitril/valsartan or to drugs of similar
- •chemical classes, patients with a known history of angioedema
- •3. Patients with mean blood pressure <=75 mmHg (systolic blood pressure i.e.
- •Doppler opening blood pressure <=90 mmHg in those pulsatile and measured by
- •Doppler method) or symptomatic hypotension
- •4. eGFR < 30 mL/min/1.73m2 as calculated by the Modification in Diet in
- •Renal Disease (MDRD) formula at Visit 1
- •5. Patients with serum potassium >5.4 mmol/L (mEq/L) at Visit 1
- •6. Hemodynamically unstable patients or those with ongoing MCS other than LVAD
- •or those with planned biventricular support
- •7. Hemodynamically significant aortic insufficiency in the opinion of the
- •investigator
- •8. Irreversible end-organ dysfunction
- •9. Previous sacubitril/valsartan use while on LVAD support
- •10. Acute coronary syndrome, stroke, transient ischemic attack, cardiac,
- •carotid or other major CV surgery, percutaneous coronary intervention (PCI) or
- •carotid angioplasty within 30 days prior to enrolment
- •11. Life-threatening or uncontrolled dysrhythmia, including symptomatic or
- •sustained ventricular tachycardia and atrial fibrillation or flutter with a
- •resting ventricular rate >110 bpm at enrolment
- •12. Any surgical or medical condition, which in the opinion of the
- •Investigator, may place the patient at higher risk from his/her participation
- •in the study, or is likely to prevent the patient from complying with the
- •requirements of the study or completing the study
- •13. Active infection with hemodynamic compromise
- •14. Hemoglobin (Hgb) <8 g/dl
- •15. Body mass index (BMI) > 45 kg/m2
- •16. Congenital heart disease
- •17. Coronary or carotid artery disease or valvular heart disease likely to
- •require surgical or percutaneous intervention within the 6 months after
- •18. Evidence of hepatic disease as determined by any one of the following: SGOT
- •(AST) or SGPT (ALT) values exceeding 3x ULN, bilirubin >1.5 mg/dl at Visit 1
- •19. Pregnant or nursing (lactating) women and women of child-bearing potential
- •unless they are using highly effective methods of contraception
研究者
相似试验
进行中（未招募）
1 期
Sacubitril/Valsartan in Left Ventricular Assist Device RecipientsHeart failureHeart failure with reduced ejection fraction Advanced Heart failureEUCTR2019-003888-22-HRniversity of Zagreb School of Medicine60
进行中（未招募）
不适用
A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage renal disease undergoing hemodialysis.chronic hepatitis C CHC virus infection in patients with end-stage renal disease ESRD undergoing hemodialysisMedDRA version: 6.1Level: PTClassification code 10019744EUCTR2004-004852-38-ITROCHE80
尚未招募
不适用
A study of Paliperidone Palmitate injection in patients of abnormal behaviorCTRI/2019/01/016865Accord Healthcare Inc
进行中（未招募）
2 期
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)Paroxysmal nocturnal hemoglobinuriaD006457JPRN-jRCT2051210179Sakagami Yohei81
进行中（未招募）
1 期
BCX9930 treatment in patients with an inadequate response to C5 inhibitorsParoxysmal Nocturnal HemoglobinuriaMedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-004438-39-SKBioCryst Pharmaceuticals Inc81